Moran Wealth Management LLC Buys 74,621 Shares of Fresenius Medical Care AG (NYSE:FMS)

Moran Wealth Management LLC raised its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 47.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 233,376 shares of the company's stock after purchasing an additional 74,621 shares during the quarter. Moran Wealth Management LLC's holdings in Fresenius Medical Care were worth $4,971,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP increased its holdings in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company's stock worth $36,000 after purchasing an additional 581 shares during the period. GAMMA Investing LLC increased its stake in Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company's stock valued at $106,000 after acquiring an additional 1,675 shares during the period. ORG Wealth Partners LLC bought a new stake in Fresenius Medical Care in the third quarter valued at about $112,000. Venturi Wealth Management LLC increased its stake in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company's stock valued at $112,000 after acquiring an additional 4,800 shares during the period. Finally, Signaturefd LLC increased its stake in Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company's stock valued at $166,000 after acquiring an additional 672 shares during the period. Institutional investors own 8.25% of the company's stock.

Fresenius Medical Care Stock Down 1.4 %

Shares of NYSE:FMS opened at $21.79 on Thursday. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $22.76. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a market capitalization of $12.79 billion, a PE ratio of 18.01, a PEG ratio of 1.02 and a beta of 0.91. The company has a 50 day moving average price of $20.75 and a two-hundred day moving average price of $20.26.

Wall Street Analysts Forecast Growth

FMS has been the topic of several research analyst reports. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a "buy" rating and a $25.60 price objective on the stock. Truist Financial upped their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. Finally, StockNews.com assumed coverage on shares of Fresenius Medical Care in a report on Saturday, November 9th. They issued a "strong-buy" rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.30.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.